Personal information

Emails & domains

Verified email addresses

Verified email domains

Websites & social links

Researchgate
Google Scholar

Other IDs

ResearcherID: I-9135-2017
Loop profile: 569213

Countries

Spain

Activities

Collapse all

Employment (4)

Centro de Investigacion Principe Felipe: Valencia, ES

2023-01-01 to present | Ramon y Cajal fellow (Cancer )
Employment
Source: Self-asserted source
Federico Lucantoni

Centro de Investigacion Principe Felipe: Valencia, ES

2021-12-01 to 2022-12-31 | Postdoctoral researcher (Advanced therapies)
Employment
Source: Self-asserted source
Federico Lucantoni

Fisabio: Valencia, ES

2019-09 to 2021-11-23 | Postdoctoral researcher (Pharmacology dept.)
Employment
Source: Self-asserted source
Federico Lucantoni

Royal College of Surgeons in Ireland: Dublin, IE

2017-10 to 2018-10 | Postdoctoral researcher (Physiology and Medical Physics)
Employment
Source: Self-asserted source
Federico Lucantoni

Education and qualifications (3)

Royal College of Surgeons in Ireland: Dublin, IE

2013-09 to 2017-10-06 | PhD in Cancer Biology (Physiology and Medical Physics)
Education
Source: Self-asserted source
Federico Lucantoni

Università degli Studi di Roma Tor Vergata Dipartimento di Biologia: Roma, Lazio, IT

2010-09 to 2012-10 | M.Sc. in Cell and Molecular Biology
Education
Source: Self-asserted source
Federico Lucantoni

Università degli Studi di Roma Tor Vergata Dipartimento di Biologia: Roma, Lazio, IT

2006-09 to 2010-07 | B.Sc in Cell and Molecular Biology
Education
Source: Self-asserted source
Federico Lucantoni

Funding (4)

Ento-cancer: Study of entosis in human cancer. Relevance of cellular cannibalism in the aggressiveness of solid tumors.

2023-07 to 2024-12 | Grant
Conselleria de Cultura, Educación y Ciencia, Generalitat Valenciana (Valencia, ES)
GRANT_NUMBER:

CIGE/2022/87
Source: Self-asserted source
Federico Lucantoni

BCL2 proteins interactions and metabolic rewiring as treatment points for colon and breast cancer

2023-01 to 2027-12 | Contract
Ministerio de Ciencia e Innovación (Madrid, ES)
GRANT_NUMBER:

RYC2021-034092-I
Source: Self-asserted source
Federico Lucantoni

DiscoMito - Discovering new therapies for TNBC: modulating cell death at the mitochondrial membrane

2021-12 to 2025-12 | Salary award
Fundación Científica Asociación Española Contra el Cáncer (Valencia, ES)
GRANT_NUMBER:

POSTD21898LUCA
Source: Self-asserted source
Federico Lucantoni

New therapeutic targets for NAFLD: autophagy, cellular senescence and mitochondrial bioenergetics in 3D models of the disease

2019-09 to 2021-08 | Salary award
Generalitat Valenciana (Valencia, ES)
GRANT_NUMBER:

APOSTD/2019/050
Source: Self-asserted source
Federico Lucantoni

Works (15)

Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less

Cell Death & Disease
2022-04 | Journal article
DOI: 10.1038/s41419-022-04789-7
Part of ISSN: 2041-4889
Source: Self-asserted source
Federico Lucantoni

Fluorescent styrylpyrylium probes for the imaging of mitochondria in live cells.

Organic & biomolecular chemistry
2021-10 | Journal article
DOI: 10.1039/d1ob01543e
PMID: 34617091
Contributors: Resta IM; Lucantoni F; Apostolova N; Galindo F
Source: Self-asserted source
Federico Lucantoni via Europe PubMed Central

BCL(X)L and BCL2 increase mitochondrial dynamics in breast cancer cell: Evidence from functional and genetic studies.

Biochimica et biophysica acta. Molecular cell research
2021-06-30 | Journal article
DOI: 10.1016/j.bbamcr.2021.119095
PMID: 34214511
Source: Self-asserted source
Federico Lucantoni

Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: are we there yet?

The Journal of pathology
2021-04-08 | Journal article
DOI: 10.1002/path.5678
PMID: 33834482
Source: Self-asserted source
Federico Lucantoni

BCL(X)L and BCL2 increase the metabolic fitness of breast cancer cells: a single-cell imaging study

Cell Death & Differentiation
2020-12-16 | Journal article
DOI: 10.1038/s41418-020-00683-x
Part of ISSN: 1350-9047
Part of ISSN: 1476-5403
Source: Self-asserted source
Federico Lucantoni

Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models

Cancers
2020-10 | Journal article | Author
DOI: 10.3390/cancers12102978
Contributors: Alice C O'Farrell; Monika A. Jarzabek; Andreas U. Lindner; Steven Carberry; Emer Conroy; Ian Miller; Kate Connor; Liam Shiels; Eugenia R. Zanella; Federico Lucantoni et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Integrating the Tumor Microenvironment into Cancer Therapy.

Cancers
2020-06 | Journal article
DOI: 10.3390/cancers12061677
PMID: 32599891
PMC: PMC7352326
Contributors: Sanegre S; Lucantoni F; Burgos-Panadero R; de La Cruz-Merino L; Noguera R; Álvaro Naranjo T
Source: Self-asserted source
Federico Lucantoni via Europe PubMed Central

The tumour microenvironment as an integrated framework to understand cancer biology

Cancer Letters
2019-10 | Journal article
DOI: 10.1016/j.canlet.2019.07.010
Part of ISSN: 0304-3835
Source: Self-asserted source
Federico Lucantoni

Metabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1

Frontiers in Cell and Developmental Biology
2018-09-11 | Journal article
DOI: 10.3389/fcell.2018.00113
Part of ISSN: 2296-634X
Contributors: Federico Lucantoni; Heiko Dussmann; Jochen H. M. Prehn
Source: Self-asserted source
Federico Lucantoni via Crossref Metadata Search

Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers.

Journal of molecular medicine (Berlin, Germany)
2018-08 | Journal article
DOI: 10.1007/s00109-018-1675-0
PMID: 30069746
Contributors: Lindner AU; Lucantoni F; Varešlija D; Resler A; Murphy BM; Gallagher WM; Hill ADK; Young LS; Prehn JHM
Source: Self-asserted source
Federico Lucantoni via Europe PubMed Central

BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose

Oncotarget
2018-05-09 | Journal article
DOI: 10.18632/oncotarget.25433
Part of ISSN: 1949-2553
Contributors: Federico Lucantoni; Heiko Düssmann; Irene Llorente-Folch; Jochen H.M. Prehn
Source: Self-asserted source
Federico Lucantoni via Crossref Metadata Search

Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells

Cell Death & Disease
2018-01 | Journal article
DOI: 10.1038/s41419-017-0039-y
Part of ISSN: 2041-4889
Contributors: Federico Lucantoni; Andreas U. Lindner; Norma O’Donovan; Heiko Düssmann; Jochen H. M. Prehn
Source: Self-asserted source
Federico Lucantoni via Crossref Metadata Search

Mislocalization of Mitochondrial Intermembrane Space Proteins

Mitochondria and Cell Death
2016 | Other
DOI: 10.1007/978-1-4939-3612-0_3
Contributors: Lorna Flanagan; Federico Lucantoni; J. H. M. Prehn
Source: Self-asserted source
Federico Lucantoni via Crossref Metadata Search

System-based BCL2 family protein signatures as predictive biomarkers in triple-negative breast cancer

Cancer Research
2016 | Journal article
DOI: 10.1158/1538-7445.AM2016-3557
ARXIV:

http://cancerres.aacrjournals.org/content/76/14_Supplement/3557
Source: Self-asserted source
Federico Lucantoni

Peptides derived from the transmembrane domain of Bcl-2 proteins as potential mitochondrial priming tools.

2014-08 | Journal article
DOI: 10.1021/cb5002679
PMID: 24905660
Contributors: Andreu-Fernández V; Genoves A; Lee TH; Stellato M; Lucantoni F; Orzáez M; Mingarro I; Aguilar MI; Pérez-Payá E
Source: Self-asserted source
Federico Lucantoni via Europe PubMed Central

Peer review (2 reviews for 2 publications/grants)

Review activity for Biochimica et biophysica acta. Molecular cell research (1)
Review activity for Nutrients. (1)
How many people are using ORCID?